Validation of the Prostatype® P-score for predicting prostate cancer specific mortality in a multiethnic U.S. veterans cohort
In this American cohort of veterans, P-score significantly predicted PCSM. Adding clinical variables minimally improved accuracy. Accuracy remained high in intermediate-risk patients, wherein there is arguably the greatest need for better risk stratification. Given P-scores can be generated rapidly in-house using a standardized RT-qPCR assay, P-score represents a robust new tool to risk-stratify newly diagnosed patients for PC death, thereby minimizing mismatched treatments.
Authors
- Andy Pao (ORCID: https://orcid.org/0000-0003-2345-6804)
- Eric Vail (ORCID: https://orcid.org/0000-0002-6578-178X)
- Anthony Sisk (ORCID: https://orcid.org/0000-0001-7262-3985)
- Michael T. Burns
- Stephen J. Freedland (ORCID: https://orcid.org/0000-0002-8104-6419)
- Anna Hoffmeyer
- Raja Khurram
- Emelie Berglund (ORCID: https://orcid.org/0000-0003-1857-307X)
- Gerald L. Andriole (ORCID: https://orcid.org/0000-0003-4033-2352)
- Haleigh Bellerose
- Trung Duong Tran
- Aubrey Jarman
- Alexandra Mack
- Sergio Sanders
- Iveth Estrada-Reyes
- Kara Bissell
- Christopher Alley
- Amal Ahmed
Institutions
- Cedars-Sinai Medical Center (US)
- University of California, Los Angeles (US)
- Institut thématique Génétique, génomique et bioinformatique (FR)
- Durham VA Health Care System (US)
Publication Details
- Journal
- Prostate Cancer and Prostatic Diseases
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1038/s41391-025-01070-8
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00